- Home
- RZLT vs EVMN Comparison
RZLT vs EVMN Comparison
Compare RZLT & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RZLT | EVMN |
|---|---|---|
| Founded | 2010 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 471.0M | 241.3M |
| IPO Year | 2011 | 2025 |
Fundamental Metrics
Financial Performance| Metric | RZLT | EVMN |
|---|---|---|
| Price | $3.87 | $5.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | $9.80 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 1.7M | 780.3K |
| Earning Date | 11-05-2026 | 11-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.47 | ★ 75.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,214.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 85.71 |
| 52 Week Low | $1.07 | $5.09 |
| 52 Week High | $11.46 | $33.20 |
Technical Indicators
Market Signals| Indicator | RZLT | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 42.25 | 20.59 |
| Support Level | $3.69 | N/A |
| Resistance Level | $4.09 | $13.35 |
| Average True Range (ATR) | 0.34 | 0.36 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 30.84 | 10.69 |
Price Performance
Historical ComparisonAbout RZLT Rezolute Inc. (NV)
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.